Full metadata record
DC FieldValueLanguage
dc.creatorFernandez-Sanmamed, M. (Miguel)-
dc.creatorFernández-Landázuri, S. (Sara)-
dc.creatorRodríguez, C. (Carmen)-
dc.creatorLozano, M.D. (María Dolores)-
dc.creatorEcheveste, J.I. (José I.)-
dc.creatorPerez-Gracia, J.L. (Jose Luis)-
dc.creatorAlegre, E. (Estibaliz)-
dc.creatorCarranza, O. (Omar)-
dc.creatorZubiri, L. (Leire)-
dc.creatorMartin-Algarra, S. (Salvador)-
dc.creatorGonzález, Á. (Álvaro)-
dc.date.accessioned2024-01-24T14:47:54Z-
dc.date.available2024-01-24T14:47:54Z-
dc.date.issued2014-
dc.identifier.citationFernandez-Sanmamed, M. (Miguel); Fernández-Landázuri, S. (Sara); Rodríguez, C. (Carmen); et al. "Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients". Clinica Chimica Acta. 429, 2014, 168 - 174es
dc.identifier.issn1873-3492-
dc.identifier.urihttps://hdl.handle.net/10171/68522-
dc.description.abstractBRAF V600 mutation has been reported in more than 50% of melanoma cases and its presence predicts clinical activity of BRAF inhibitors (iBRAF). We evaluated the role of MIA, S100 and LDH to monitor iBRAF efficiency in advanced melanoma patients presenting BRAF V600 mutations. This was a prospective study of melanoma patients harboring the BRAF V600 mutation and treated with iBRAF within a clinical trial (dabrafenib) or as part of an expanded access program (vemurafenib). MIA, S100 and LDH were analyzed in serum at baseline, and every 4–6 weeks during treatment. Eighteen patients with melanoma stages IIIc–IV were enrolled with 88.8% of response rate to iBRAF. Baseline concentrations of all the tumor markers correlated with tumor burden. MIA and S100 concentrations decreased significantly one month after the beginning of treatment and, upon progression, their concentrations increased significantly above the minimum levels previously achieved. MIA levels lower than 9 μg/L one month after the beginning of treatment and S100 concentrations lower than 0.1 μg/L at the moment of best response were associated with improved progression-free survival. In conclusion, MIA and S100 are useful to monitor response in melanoma patients treated with iBRAFes_ES
dc.description.sponsorshipThis work was supported by a “Fondo de Investigación Sanitaria” grant [PI11/02119] and the Rio Hortega contract from the Spanish Economy Ministry to MF Sanmamedes_ES
dc.language.isoenges_ES
dc.publisherElsevier BVes_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/Proyectos de Investigación en Salud/PI11%2F02119/ES/Búsqueda de marcadores tumorales asociados a exosomas circulantes en pacientes con melanomaes_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.subjectMelanomaes_ES
dc.subjectBRAFes_ES
dc.subjectTherapyes_ES
dc.subjectS100es_ES
dc.subjectMIAes_ES
dc.subjectTumor markeres_ES
dc.titleRelevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteAll rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.es_ES
dc.identifier.doi10.1016/j.cca.2013.11.034-
dadun.citation.endingPage174es_ES
dadun.citation.publicationNameClinica Chimica Actaes_ES
dadun.citation.startingPage168es_ES
dadun.citation.volume429es_ES
dc.identifier.pmid24333389-

Files in This Item:
File
relevance of mia.pdf
Description
Size
477.43 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.